$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

{"summary": "Commenter warns that Perceptive Advisors and OrbiMed 13F filings show a large put position against SLS, suggesting hedging or caution.", "reason": "The author provides a concrete catalyst (institutional 13F filings showing bearish positioning) as the basis for their investment judgment.", "ideas": [{"symbol": "SLS", "direction": "avoid", "thesis": "The author cites recent 13F filings from Perceptive Advisors and OrbiMed showing OrbiMed made a huge put bet against SLS, along with other biotech majors. The mechanism is that large institutional investors are positioned bearishly, implying they possess information or conviction that retail lacks. The author suggests that anyone committed to SLS should at least hedge, framing the institutions as knowing more than retail investors.", "thesis_short": "OrbiMed 13F shows huge SLS put bet", "quote": "Orbimed made a HUGE put bet against SLS. Couple other of the Bio majors too. If you are committed to SLS maybe at least hedge. They know more than we do, inarguably.", "confidence": 0.6, "sentiment": -0.6, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}